Ocular Therapeutix stock hits 52-week high at $11.78
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix Inc stock price live, this page displays NASDAQ OCUL stock exchange data. View the OCUL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ocular Therapeutix Inc real time stock price chart below.
What Is the Ocular Therapeutix Inc Stock Price Today?
The Ocular Therapeutix Inc stock price today is 12.08.
What Is the Stock Symbol for Ocular Therapeutix Inc?
The stock symbol for Ocular Therapeutix Inc is ""OCUL.""
What Stock Exchange Does Ocular Therapeutix Inc Trade On?
Ocular Therapeutix Inc is listed and trades on the NASDAQ stock exchange.
Is Ocular Therapeutix Inc a Good Stock to Buy?
Determining whether Ocular Therapeutix Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OCUL quote. (ISIN: US67576A1007)
What Is the Ocular Therapeutix Inc Stock Price Today?
The Ocular Therapeutix Inc stock price today is 12.08.
What Is the Stock Symbol for Ocular Therapeutix Inc?
The stock symbol for Ocular Therapeutix Inc is ""OCUL.""
What Stock Exchange Does Ocular Therapeutix Inc Trade On?
Ocular Therapeutix Inc is listed and trades on the NASDAQ stock exchange.
Is Ocular Therapeutix Inc a Good Stock to Buy?
Determining whether Ocular Therapeutix Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OCUL quote. (ISIN: US67576A1007)
12.08
-0.13(-1.06%)
Closed·
After Hours
12.080.00(0.00%)
·
Fair Value
An estimate of a Ocular Therapeutix Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.94
12.35
52 wk Range
5.79
12.35
OCUL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
More Info
Fair Value
An estimate of a Ocular Therapeutix Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.9412.35
52 wk Range
5.7912.35
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OCUL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Ocular Therapeutix Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
17.92
Upside
+48.32%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
- Ocular Therapeutix stock hits 52-week high at $11.78
- Investing.com
- Clear Street holds OCUL stock at Buy, target at $18
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
Ocular Therapeutix Inc Company Profile
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix Inc SWOT Analysis
Retinal Revolution | Ocular Therapeutix shifts focus to retina diseases, positioning for growth in diabetic retinopathy and wet AMD markets with innovative treatments |
Promising Pipeline | Explore axpaxli's potential as a blockbuster drug for diabetic retinopathy, offering extended durability and improved patient outcomes |
Glaucoma Breakthrough | Paxtrava shows comparable or superior efficacy to existing treatments, with potential for re-dosing and improved long-term management |
Financial Outlook | Analysts set price targets ranging from $15 to $24, with a strong cash position of $483 million providing runway into 2028 despite higher expenses |
Ocular Therapeutix Inc Earnings Call Summary for Q4/2024
- Q4 2024 EPS of -$0.29 missed forecast; revenue at $17.08M slightly below expectations. Stock rose 0.84% in premarket trading.
- Strong cash position of $392M as of Dec 31, 2024. Focus on developing treatments for retinal diseases like wet AMD and NPDR.
- CEO emphasized commitment to innovation, aiming to set new standards in treatment durability and outcomes for retinal care.
- Projected negative EPS through FY2025. FDA feedback on trials and top-line data in 2026 are key milestones for future performance.
- Analysts' earnings expectations revised downward, but company maintains strong liquidity with a current ratio of 13.01.
Last Updated: 03/03/2025, 15:22
Read Full TranscriptCompare OCUL to Peers and Sector
Metrics to compare | OCUL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOCULPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.0x | −1.4x | −0.5x | |
PEG Ratio | −0.87 | 0.00 | 0.00 | |
Price/Book | 7.2x | 2.0x | 2.6x | |
Price / LTM Sales | 32.3x | 1.8x | 3.2x | |
Upside (Analyst Target) | 41.1% | 135.3% | 41.2% | |
Fair Value Upside | Unlock | 27.7% | 6.2% | Unlock |
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.92
(+48.32% Upside)
Earnings
Latest Release
May 05, 2025
EPS / Forecast
-0.38 / -0.29
Revenue / Forecast
10.70M / 17.07M
People Also Watch
FAQ
What Stock Exchange Does Ocular Therapeutix Inc Trade On?
Ocular Therapeutix Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Ocular Therapeutix Inc?
The stock symbol for Ocular Therapeutix Inc is "OCUL."
What Is the Ocular Therapeutix Inc Market Cap?
As of today, Ocular Therapeutix Inc market cap is 1.92B.
What Is Ocular Therapeutix Inc's Earnings Per Share (TTM)?
The Ocular Therapeutix Inc EPS (TTM) is -1.15.
When Is the Next Ocular Therapeutix Inc Earnings Date?
Ocular Therapeutix Inc will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is OCUL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Ocular Therapeutix Inc Stock Split?
Ocular Therapeutix Inc has split 0 times.
How Many Employees Does Ocular Therapeutix Inc Have?
Ocular Therapeutix Inc has 274 employees.
What is the current trading status of Ocular Therapeutix Inc (OCUL)?
As of 29 Jul 2025, Ocular Therapeutix Inc (OCUL) is trading at a price of 12.08, with a previous close of 12.08. The stock has fluctuated within a day range of 11.94 to 12.35, while its 52-week range spans from 5.79 to 12.35.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.